Natus Medical (NTUS) Q1 2020 Earnings Call Transcript

Natus Medical (NTUS) Q1 2020 Earnings Call Transcript

Good afternoon, everyone, and thank you for joining us today to review our results for the first-quarter 2020.. On the call today from Natus is Jonathan Kennedy, Natus' president and chief executive officer; and Drew Davies, Natus' executive vice president and chief financial officer.. We will open the call for your questions.. I'd now like to turn the call over to Jonathan Kennedy, president and chief executive officer of Natus Medical.. We've made strategic investments in inventory to help mitigate potential supply chain disruptions and we have taken actions to reduce cost, including reducing travel and discretionary expenses.. Revenue for the quarter was $109.4 million and non-GAAP earnings per share was $0.04.. Overall, our revenue declined 2.8% versus the same quarter in the prior year after adjusting for divestitures.. Despite seeing significant impact from the COVID-19 pandemic during the first quarter, our neuro market continued to perform well, growing at 4.7% versus the same year -- same period last year.. Our newborn care and hearing and balance markets declined during the quarter due to a worldwide softening of demand.. Our neuro market, which includes our industry-leading neurodiagnostic solutions as well as our neurosurgery and neurocritical care products performed well during